2 Minute Quick Tips from the APSHO Experts

APs: Need some clinical advice? Got 2 minutes? Watch our clinical oncology experts talk about the latest topics that will get you up to speed on current advances in the field. Here you’ll find a range of topics where you can increase your knowledge quickly and then, when you have more than 2 minutes, you can participate in a deeper dive on each topic by accessing the full accredited version at JADPRO CE. Come back often as we are continually updating our 2 minute tips!


Search by:

What is the appropriate use of new agents for mantle cell lymphoma?

Barbara Rogers, CRNP, MN, AOCN, ANP-BC

Watch Video

Barbara Rogers, CRNP, MN, AOCN, ANP-BC, on treating mantle cell lymphoma.

What is the potential of emerging therapies?

Barbara Rogers, CRNP, MN, AOCN, ANP-BC

Watch Video

Barbara Rogers, CRNP, MN, AOCN, ANP-BC, on treating aggressive B-cell lymphomas.

What are the current treatments for relapsed/refractory DLBCL?

Barbara Rogers, CRNP, MN, AOCN, ANP-BC

Watch Video

Barbara Rogers, CRNP, MN, AOCN, ANP-BC, on treating aggressive B-cell lymphomas.

How do I manage minimal residual disease?

Jean A. Ridgeway, DNP, APN, NP-C, AOCN

Watch Video

Jean A. Ridgeway, DNP, APN, NP-C, AOCN, on treating acute myeloid leukemia.

What are the best ways to manage the side effects of AML therapies?

Jean A. Ridgeway, DNP, APN, NP-C, AOCN

Watch Video

Jean A. Ridgeway, DNP, APN, NP-C, AOCN, on treating acute myeloid leukemia.

What are the germline mutations in patients predisposed to MPN/MDS?

Sandra E. Kurtin, PhDc, ANP-C, AOCN

Watch Video

Sandra E. Kurtin, PhDc, ANP-C, AOCN, on treating Ph- myeloproliferative neoplasms.

What should I know about the JAK-STAT biochemical signaling pathway?

Sandra E. Kurtin, PhDc, ANP-C, AOCN

Watch Video

Sandra E. Kurtin, PhDc, ANP-C, AOCN, on treating Ph- myeloproliferative neoplasms.

What are the latest WHO disease definitions for diagnosing myeloproliferative neoplasms?

Sandra E. Kurtin, PhDc, ANP-C, AOCN

Watch Video

Sandra E. Kurtin, PhDc, ANP-C, AOCN, on treating Ph- myeloproliferative neoplasms.

What are the mechanisms of action and use of PD-1 inhibitors in the treatment of classical Hodgkin lymphoma?

Patrick J. Kiel, PharmD, BCPS, BCOP

Watch Video

Patrick J. Kiel, PharmD, BCPS, BCOP, on treating Hodgkin lymphoma.

What are the emerging therapies for relapsed or refractory classical Hodgkin lymphoma?

Patrick J. Kiel, PharmD, BCPS, BCOP

Watch Video

Patrick J. Kiel, PharmD, BCPS, BCOP, on treating hodgkin lymphoma.

What are the best care strategies for patients with relapsed/refractory multiple myeloma who need maintenance therapy?

Patrick J. Kiel, PharmD, BCPS, BCOP

Watch Video

Patrick J. Kiel, PharmD, BCPS, BCOP: on treating multiple myeloma.

What are the prognostic factors and risk-adaptive strategies for making treatment decisions in follicular lymphoma?

Amy Goodrich, MSN, CRNP

Watch Video

Amy Goodrich, MSN, CRNP, on treating follicular lymphoma.

What are the latest data on newly approved agents for primary, relapsed, and refractory follicular lymphoma?

Amy Goodrich, MSN, CRNP

Watch Video

Amy Goodrich, MSN, CRNP, on treating follicular lymphoma.

What are the best strategies for managing the side effects of medications for follicular lymphoma?

Amy Goodrich, MSN, CRNP

Watch Video

Amy Goodrich, MSN, CRNP, on treating follicular lymphoma.

How do I incorporate emerging therapies into treatment plans for patients with CLL?

Amy Goodrich, MSN, CRNP

Watch Video

Amy Goodrich, MSN, CRNP, on treating chronic lymphocytic leukemia.

How useful is biomarker testing in choosing patients for immunotherapy?

Whitney Lewis, PharmD, BCOP

Watch Video

Whitney Lewis, PharmD, BCOP, on biomarker testing.

What is the rationale for sequencing and combining immunotherapy with chemotherapy?

Whitney Lewis, PharmD, BCOP

Watch Video

Whitney Lewis, PharmD, BCOP, on using immunotherapy vs chemotherapy.

What combination therapies lead to more durable responses?

Brianna Hoffner, MSN, ANP-BC, AOCNP, and Laura J. Zitella, MS, RN, ACNP-BC, AOCN

Watch Video

Brianna Hoffner, MSN, ANP-BC, AOCNP, and Laura J. Zitella, MS, RN, ACNP-BC, AOCN, on current data on effective immunotherapies.

What are the differences between early and late adverse effects of immunotherapy treatments?

Brianna Hoffner, MSN, ANP-BC, AOCNP, and Laura J. Zitella, MS, RN, ACNP-BC, AOCN

Watch Video

Brianna Hoffner, MSN, ANP-BC, AOCNP, and Laura J. Zitella, MS, RN, ACNP-BC, AOCN, on adverse effects of immunotherapy.

How do we understand response patterns in immunotherapy?

Brianna Hoffner, MSN, ANP-BC, AOCNP

Watch Video

Brianna Hoffner, MSN, ANP-BC, AOCNP, on assessing response in immunotherapy.

How do the side effects of immunotherapy and chemotherapy agents differ?

Brianna Hoffner, MSN, ANP-BC, AOCNP

Watch Video

Brianna Hoffner, MSN, ANP-BC, AOCNP, on immunotherapy and chemotherapy side effects.

Copyright © 2010-2018 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.